# US 2016/0256672 A1 · Induced pluripotent stem cell-derived hepatocyte based bioartificial liver device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256672 A1
- Document ID: US20160256672A1
- Status: Published application
- Kind: A1
- Application number: 15/019,938
- Filed: 2016-02-09
- Published: 2016-09-08
- Earliest claimed: 2015-02-10
- Assignees: Cedars-Sinai Medical Center
- Applicants: Cedars-Sinai Medical Center
- Inventors: Vaithilingaraja Arumugaswami; Clive Svendsen
- Web page: https://patentgrep.com/patent/US20160256672A1

## CPC

- C12N 5/067: {Hepatocytes}
- A61M 1/3489: {by biological cells, e.g. bioreactor}
- C12N 5/0075: {using microcarriers}
- A61M 2202/09: Body tissue
- C12N 2500/62: DMSO
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/148: Transforming growth factor alpha [TGF-a]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2501/237: Oncostatin M [OSM]
- C12N 2501/39: Steroid hormones
- C12N 2501/415: Wnt; Frizzeled
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps. Thus, the iPSC hepatocytes in the bioartificial liver device maintained the secretory function and exhibited cell maturation.

## Claims

### Claim 1

A bioreactor module for a bioartificial liver device, the module comprising:
a continuous flow bioreactor; and
a quantity of induced pluripotent stem cell derived hepatocytes (i-Heps) that are fixed to microcarrier beads in the extracapillary space of the continuous flow bioreactor.

### Claim 2 (depends on 1)

The bioreactor module of claim 1, wherein the continuous flow bioreactor is a hollow-fiber bioreactor.

### Claim 3 (depends on 1)

The bioreactor module of claim 1, wherein the continuous flow bioreactor is in fluid communication with a patient's plasma.

### Claim 4 (depends on 1)

The bioreactor module of claim 1, wherein the microcarriers have a pore size of less than 1 μm.

### Claim 5 (depends on 1)

The bioreactor module of claim 1, wherein the microcarriers are coated with laminin.

### Claim 6 (depends on 1)

The bioreactor module of claim 1, wherein the microcarriers have a particle size from 60 to 87 μm.

### Claim 7 (depends on 1)

The bioreactor module of claim 1, wherein the microcarriers comprise dextran.

### Claim 8 (depends on 1)

The bioreactor module of claim 1, wherein the bioreactor has hollow fibers with 0.21 μm pores.

### Claim 9 (depends on 3)

The bioreactor module of claim 3, wherein an ultrafiltrate generator is in fluid communication with a patient's blood.

### Claim 10

A method of using a bioartificial liver device in order to support, enhance, or replace liver function of a patient, the method comprising:
(a) removing plasma from a patient's blood stream;
(b) pumping the plasma through a bioartificial liver module, wherein the bioartificial liver module includes a quantity of induced pluripotent stem cell derived hepatocytes (iHeps) that are fixed to microcarrier beads in the extracapillary space of the bioartificial liver module; and
(c) returning the plasma to a patient's blood stream.

### Claim 11 (depends on 10)

The method of claim 10, wherein the iHeps are cultured in a microcarrier suspension culture prior to introduction into the extracapillary space of the bioartificial liver module.

### Claim 12 (depends on 11)

The method of claim 11, wherein the iHeps are matured in a continuous flow bioreactor while fixed to microcarrier beads prior to pumping the plasma through the bioartificial liver module.

### Claim 13 (depends on 10)

The method of claim 10, wherein the microcarriers have a pore size of less than 1 μm.

### Claim 14 (depends on 10)

The method of claim 10, wherein the microcarriers are coated with laminin.

### Claim 15 (depends on 10)

The method of claim 10, wherein the microcarriers have a particle size from 60 to 87 μm.

### Claim 16 (depends on 10)

The method of claim 10, wherein the microcarriers comprise dextran.

### Claim 17 (depends on 10)

The method of claim 10, wherein the bioreactor has hollow fibers with 0.21 μm pores.

### Claim 18

A method of differentiating a human pluripotent stem cell into a cell capable of hepatic function comprising:
(a) providing a quantity of induced pluripotent stem cells (pSCs);
(b) culturing the pSCs in the presence of at least one differentiation agent, wherein the at least one differentiation agent is capable of differentiating the pSCs into an induced pSC-derived hepatocyte (iHep);
(c) harvesting the iHep and pre-culturing the iHep on microcarrier beads; and
(d) further culturing the iHep on the microcarrier beads in a continuous flow bioreactor to form a mature hepatocyte from the iHep.

### Claim 19 (depends on 18)

The method of claim 18, wherein the continuous flow bioreactor is a hollow fiber bioreactor (HFB).

### Claim 20 (depends on 18)

The method of claim 18, wherein the microcarriers have a pore size of less than 1 μm.

### Claim 21 (depends on 18)

The method of claim 18, wherein the iHep is further cultured in the continuous flow bioreactor until the expression of AFP is reduced 50 fold.

### Claim 22 (depends on 18)

The method of claim 18, wherein the step (c) is performed between day 16-day 21 of a differentiation protocol.

### Claim 23 (depends on 18)

The method of claim 18, wherein the step (c) is performed on day 19 of a differentiation protocol.

### Claim 24 (depends on 18)

The method of claim 18, wherein the microcarriers are coated with laminin.

### Claim 25 (depends on 18)

The method of claim 18, wherein the bioreactor has hollow fibers with 0.21 μm pores.

### Claim 26 (depends on 18)

The method of claim 18, wherein the microcarriers have a particle size from 60 to 87 μm.

### Claim 27 (depends on 18)

The method of claim 18, wherein the microcarriers comprise dextran.

### Claim 28 (depends on 18)

The method of claim 18, further comprising:
(c) culturing the pSCs in the presence of at least one second differentiation agent comprising Activin A;
(d) culturing of the pSCs in the presence of at least one third differentiation agent comprising VEGF; and
(e) culturing the pSCs in the presence of at least one fourth differentiation agent comprising EGF, TGF-α, and dexamethasone, bFGF, and BMP4.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cells are further cultured in the presence of at least a first maturation agent comprising: HGF, dexamethasone, and oncostatin M.

### Claim 30 (depends on 18)

A cell line, comprising one or cells produced by the method of claim 18.

### Claim 31

A method of differentiating a human pluripotent stem cell into a cell capable of hepatic function comprising:
(a) providing a quantity of human pluripotent stem cells (pSCs);
(b) culturing the pSCs in the presence of at least one differentiation agent, wherein the at least one differentiation agent is capable of differentiating the pSCs into an induced pSC-derived hepatocyte (iHep); and
(c) wherein the culturing is at least partially performed in a continuous flow bioreactor with the pSCs or cells differentiated from the pSCs adhered to microcarrier beads.

### Claim 32 (depends on 31)

The method of claim 31, wherein the continuous flow bioreactor is a hollow fiber bioreactor (HFB).

### Claim 33 (depends on 31)

The method of claim 31, wherein the microcarriers have a pore size of less than 1 μm.

### Claim 34 (depends on 31)

The method of claim 31, wherein the iHep is further cultured in the continuous flow bioreactor until the expression of AFP is reduced 50 fold.

### Claim 35 (depends on 31)

The method of claim 31, wherein step (c) is performed between day 16-day 21 of a differentiation protocol.

### Claim 36 (depends on 31)

The method of claim 31, wherein step (b) is performed between day 12-day 21 of a differentiation protocol.

### Claim 37 (depends on 31)

The method of claim 31, wherein step (c) is performed on day 19 of a differentiation protocol.

### Claim 38 (depends on 31)

The method of claim 31, wherein step (c) is performed for an entire differentiation protocol.

### Claim 39 (depends on 31)

The method of claim 31, wherein the microcarriers are coated with laminin.

### Claim 40 (depends on 31)

The method of claim 31, wherein the bioreactor has hollow fibers with 0.21 μm pores.

### Claim 41 (depends on 31)

The method of claim 31, wherein the microcarriers have a particle size of 60-87 μm.

### Claim 42 (depends on 31)

The method of claim 31, wherein the microcarriers are dextran microcarrier beads.
